Fate Therapeutics (FATE) Tops Q3 EPS by 2c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Goldman lowers Mattel rating to Sell on macro and execution risks; shares dip
• AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
• UBS Reiterates Buy Rating on Comfort Systems USA (FIX) Amid Robust Demand Environment